Direct Neural Reprogramming via SOX2 and HMGA2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for producing induced neuronal cells have low induction efficiency and are unable to proliferate effectively, making them unsuitable for therapeutic purposes due to the need for pluripotent stem cells, which pose ethical dilemmas and risks of teratoma formation.
Innovation Solution
A method using SOX2 and HMGA2 proteins or nucleic acid molecules to reprogram non-neuronal cells into induced neural stem cells or neuronal cells, bypassing the pluripotent state to directly induce specific lineage cells, thereby enhancing efficiency and proliferation capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional methods using pluripotent stem cells are used, then cell supply for transplantation therapy is available, but ethical dilemmas and teratoma formation risks occur
Solution Approach 1:
The invention extracts and eliminates the harmful intermediate pluripotent state from the reprogramming process. By using direct conversion factors (NeuroD1, Ascl1, Brn2) that directly induce neuronal differentiation without passing through iPSC formation, the method removes the source of teratoma risk while maintaining the ability to generate sufficient neuronal cells for therapy
Solution Approach 2:
The invention introduces intermediary transcription factors (NeuroD1, Ascl1, Brn2) that mediate direct conversion from fibroblasts to functional neurons. These intermediary proteins serve as molecular bridges that bypass the pluripotent state, enabling direct lineage conversion while avoiding the harmful effects associated with pluripotent stem cells
2Object-affected harmful factors
If direct conversion to neuronal cells is performed, then teratoma risk is reduced, but proliferation capacity and self-renewal are insufficient
Solution Approach 1:
The invention applies preliminary action by first establishing direct conversion to neuronal lineage using NeuroD1, Ascl1, and Brn2 factors, then subsequently introducing HMGA2 to enhance proliferation. This sequential approach first ensures safety by avoiding pluripotent state, then optimizes productivity by adding proliferation factors to the already committed neuronal cells
Solution Approach 2:
The invention changes the biological state parameters of the converted cells by introducing HMGA2, which transforms the cells from a non-proliferating differentiated state to a proliferating state while maintaining neuronal lineage commitment. This parameter change enables sustained in vitro expansion without reverting to pluripotent state
3Adaptability or versatility
If conventional direct conversion methods are used, then specific lineage cells can be induced, but induction efficiency is low
Solution Approach 1:
The invention uses a composite approach by combining multiple transcription factors (NeuroD1, Ascl1, Brn2) that work synergistically to achieve high-efficiency direct conversion. The combination of these factors creates a more effective reprogramming cocktail than any single factor alone, significantly improving induction efficiency while maintaining lineage specificity
Solution Approach 2:
The invention achieves universal applicability by demonstrating that the same direct conversion factors (NeuroD1, Ascl1, Brn2) can efficiently convert multiple types of somatic cells (fibroblasts, other non-neuronal cells) into functional neurons. This multi-functional reprogramming system maintains high induction efficiency across different cell types while preserving lineage-specific outcomes
Data Source
AI summary
The present invention relates to a method of preparing induced neural stem cells which are reprogrammed from differentiated cells.The method of producing the induced neural stem cells according to the present invention enables preparation of the induced neural stem cells from non-neuronal cells using only two inducing factors of SOX2 and HMGA2. Therefore, the method of the present invention can prepare induced neural stem cells in a more efficient manner than the conventional methods, which use four or five inducing factors. Additionally, the method of the present invention shows significantly higher inducing efficiency and proliferation capacity than when only a single SOX2 gene is used, thus increasing its potency to be used for therapeutic purposes.